ALX/FPR2 Receptor Activation by Inflammatory (fMLFII) and Pro-resolving (LXA(4) and RvD3) Agonists

炎症激动剂(fMLFII)和促消退激动剂(LXA(4)和RvD3)激活ALX/FPR2受体

阅读:1

Abstract

Nine structures of the ALX/FPR2 receptor are currently deposited in the PDB. In seven structures, the receptor is complexed with formylated peptides. In all seven structures, residue D106 is indicated as acting in the ALX/FPR2 receptor activation in addition to residues R201 and R205. Here, we performed docking simulations and long-term molecular dynamics simulations to investigate the ALX/FPR2 receptor activation using two pro-resolution agonists (lipoxin A4 (LXA(4)) and resolvin D3 (RvD3)) and a formylated peptide pro-inflammatory agonist (fMLFII). We have analyzed the receptor's activation state, electrostatic interactions, and the binding affinities of the complexes receptor-agonist using the MM/PBSA approach. The results showed that LXA(4) and fMLFII kept the receptor in an active state by a higher simulation time when compared to RvD3. Only R201 and R205 were considered key residues in the ALX/FPR2 receptor activation by all agonists. The electrostatic interaction analysis confirmed the importance of these residues in ALX/FPR2 receptor activation. Furthermore, only fMLLII showed interactions with residue D106. The binding free energy calculations indicated that the electrostatic component significantly binds the agonists to the receptor. Overall, the results from this study provide new insights into the ALX/FPR2 receptor activation mechanisms, reinforcing the role of critical residues and interactions in the binding of pro-resolution and inflammatory agonists.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。